Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 02.11.2023
Vectron Systems AG
acardo acquisition and digitisation strategy have positive influence; risk
from purchase price payment practically non-existent
After the fiscalisation effect has largely expired, Vectron Systems AG is
currently in a transformation process. Their focus is on the expansion of
digital services, so that in future the predominant part of Vectr [ … ]
Wed, 01.11.2023
Ikonisys SA
Strategic alliance with Biocare Medical is a game changer
Ikonisys announced that it has entered a strategic partnership with Biocare
Medical which will take advantage of each firm’s respective strengths to
drive and deepen their leading-edge technology positions. Ikonisys, in
addition, will substantially expand its global footprint [ … ]
Tue, 31.10.2023
PSI AG
First Berlin Equity Research has published a research update on PSI SE
(ISIN: DE000A0Z1JH9). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 32.00 to EUR 30.00.
Abstract:
PSI's order intake climbed 25.5% to €69m (Q3/22: €55m) in Q3/23 and was up
16.1% at €238m (9M/22: €205m) after nine [ … ]
Wed, 25.10.2023
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and increased the price target from EUR 44.00 to EUR 50.00.
Abstract:
DRAG has raised base-case revenue and EBITDA guidance for 2023 by 20.6% and
16.7% respectively and for 2024 by 11.1% and [ … ]
Wed, 25.10.2023
USU Software AG
Q3e: Sequential improvements as headwinds remain; chg.
USU will report Q3 figures on 22 November, which are seen to show
sequential improvements compared to the previous quarter, especially on the
margin side. This comes despite ongoing headwinds
in connection with longer sales cycles, particularly in the license
business, which led to a w [ … ]
Wed, 25.10.2023
Vectron Systems AG
9 months 2023: Significant increase in sales and earnings achieved; 2023
forecasts raised and target price increased slightly; BUY
According to preliminary figures, Vectron Systems AG (short: Vectron)
achieved a significant growth in turnover and result in the third quarter,
which seamlessly continues the positive development of the previo [ … ]
Mon, 23.10.2023
Eloro Resources Ltd.
The importance of ore sorting and stripping ratios
After Eloro Resources published the initial mineral resource estimate (MRE)
for the Iska Iska silver-tin polymetallic project in the Bolivian Potosi
Department, the share price came under significant pressure. We believe
this was based on certain misconceptions specifically about the impac [ … ]
Mon, 23.10.2023
ad pepper media International N.V.
First Berlin Equity Research hat ein Research Update zu ad pepper media
International N.V. (ISIN: NL0000238145) veröffentlicht. Analyst Dr. Karsten
von Blumenthal bestätigt seine BUY-Empfehlung und senkt das Kursziel von
EUR 3,50 auf EUR 3,00.
Zusammenfassung:
ad pepper media (APM) hat vorläufige Zahlen für das dritte Quarta [ … ]
Fri, 20.10.2023
First Tin Plc
Business Development 1. HY 2023
Overall, First Tin's first half of the year marked a period of significant
strategic progress, establishing a robust foundation for future development
and production that adheres to the highest environmental standards and
satisfies the growing demand for responsibly sourced tin. The company
achieved substant [ … ]
Thu, 19.10.2023
Sernova Corp
First Berlin Equity Research has initiated coverage on Sernova Corp (ISIN:
CA81732W1041). Analyst Christian Orquera's rating is BUY with a price
target of CAD3.80 (USD2.80; €2.60).
Abstract:
Sernova Corp (Sernova) is a Canadian, clinical-stage biotech company
developing cell therapeutics towards 'functional cures' for chronic
debilitating [ … ]